Lausanne, Switzerland, December 19, 2023

Hycann Health today announced the launch of its business operations based on the campus of Biopôle.

“Since its legalization in August of 2022, medical cannabis has become a new treatment option in Switzerland and demand for continuous GMP-compliant supply is expected to grow.” said Daniel Seidl, CEO of Hycann Health.  He added: "Over the past two years, our team has built a robust seed to sale supply chain, with a dedicated network of trusted suppliers and partners, ready to deliver industry-leading cannabis cultivars to pharmacies.”

The company expects to launch product distribution with pharmacies across Switzerland once the pending Swissmedic license application for regulatory approval has been granted.  Hycann Health's EU-GMP manufactured API’s are sourced from a selection of experienced cannabis growers and manufacturers.

About Hycann Health

Hycann Health is an international distributor of cannabis active pharmaceutical ingredients.  We are driven by a commitment to support cannabinoid-based therapies through quality, compliance, operational excellence and innovation.

About the Biopôle campus

Based in Lausanne, Biopôle is one of the largest life sciences campuses in Europe. It supports emerging enterprises via its collaborative ecosystem. Pioneering spaces like StartLab, Superlab and the Digital Health Hub encourage people to connect, and its Start-up Fund and Vanguard Accelerator offer financial and strategic support. In 2023, the vibrant community includes 140 companies, 25 academic research groups and 2,500 people, developing cutting-edge innovations in pharma, biotech and digital health.